Jose Portoles
Overview
Explore the profile of Jose Portoles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marques Vidas M, Portoles J, Cobo M, Gorriz J, Nunez J, Cases A
J Am Heart Assoc
. 2025 Mar;
14(5):e037363.
PMID: 40028884
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, sharing significant overlap in prevalence and pathophysiological mechanisms. This coexistence, termed cardiorenal syndrome (CRS), often leads to anemia, which exacerbates...
2.
Coll E, Cigarran S, Portoles J, Cases A
Toxins (Basel)
. 2024 Nov;
16(11).
PMID: 39591250
The gut dysbiosis present in chronic kidney disease (CKD) has been associated with anemia. Factors such as the accumulation of gut-derived uremic toxins, increased gut barrier permeability-induced inflammation, and a...
3.
Portoles J, Crespo M, Martinez Belotto M, Martinez Morales E, Calatayud Aristoy E, Mora Lopez P, et al.
Clin Kidney J
. 2024 Oct;
17(10):sfae269.
PMID: 39372236
Background: Post-transplant anemia is a prevalent yet often overlooked condition that poses significant risks. Current guidelines consider the same treatment recommendations and goals for these patients as for chronic kidney...
4.
Marques Vidas M, Lopez-Sanchez P, Sanchez-Briales P, Lopez Illazquez M, Portoles J
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274378
GLP-1 receptor agonists (GLP-1RAs) have emerged as fundamental components in the treatment of type 2 diabetic patients (T2DM) with chronic kidney disease (CKD). The oral formulation represents a novel therapeutic...
5.
Valdenebro M, Portoles J, Serrano Salazar M, Munoz Sanchez A, Alameda-Aguado I, Martin Rodriguez L, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274298
: Acute kidney injury (AKI) significantly disrupts vital renal functions and is a common and serious condition in intensive care units (ICUs). AKI leads to extended hospital stays, increases mortality...
6.
Dasgupta I, Bagnis C, Floris M, Furuland H, Gallego Zurro D, Gesualdo L, et al.
Clin Kidney J
. 2024 Aug;
17(8):sfae205.
PMID: 39135937
Anaemia is common in chronic kidney disease (CKD) and has a significant impact on quality of life (QoL), work productivity and outcomes. Current management includes oral or intravenous iron and...
7.
Sanchez-Briales P, Marques Vidas M, Lopez-Sanchez P, Lopez-Illazquez M, Martin-Testillano L, Vedat-Ali A, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592682
(1) Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors...
8.
Portoles J, Serrano Salazar M, Gonzalez Pena O, Gallego Dominguez S, Vera Rivera M, Caro Espada J, et al.
Clin Kidney J
. 2023 Dec;
16(12):2493-2502.
PMID: 38046036
Background: Current guidelines establish the same hemoglobin (Hb) and iron biomarkers targets for hemodialysis (HD) and peritoneal dialysis (PD) in patients receiving erythropoiesis-stimulating agents (ESAs) even though patients having PD...
9.
Portoles J, Martin-Malo A, Martin-Rodriguez L, Fernandez-Fresnedo G, de Sequera P, Sanchez J, et al.
Nefrologia (Engl Ed)
. 2023 Nov;
43(5):517-530.
PMID: 37993379
Anemia is a common complication of chronic kidney disease (CKD) and is associated with a decrease in quality of life and an increased risk of transfusions, morbidity and mortality, and...
10.
Cases A, de Sequera P, Quiroga B, Puchades M, Martin-Rodriguez L, Gorriz J, et al.
Nefrologia (Engl Ed)
. 2023 Nov;
43(5):651-652.
PMID: 37940479
No abstract available.